Category: Navigating Regulatory Landscapes in Latin America

Explores the regulatory requirements and best practices for conducting clinical trials in Latin America, focusing on medical devices and biopharmaceuticals.

  • Medexa Ecuador Registration Holder vs bioaccess® LATAM Market Access

    Medexa is a Quito-based regulatory affairs firm that publishes a “Representación Legal y Holding Regulatorio” service for foreign manufacturers that want to register products in Ecuador without setting up a local company. The service page is at medexapro.com/representacion-legal-y-holding-regulatorio (retrieved 20 October 2026). This article uses only what Medexa publishes, then compares it with the multi-country market access offer from bioaccess®.

    What Medexa publishes

    Medexa says it acts as titular regulatorio in Ecuador for foreign manufacturers with no local structure, “especialmente en dispositivos médicos.” The holding page lists two parts:

    • Representación regulatoria: formal action before ARCSA, Agrocalidad and other authorities; acting as the local solicitante for registros sanitarios and notificaciones sanitarias; coordination with manufacturers, distributors and logistics operators; follow-up of requirements, renewals and post-registration processes.
    • Holding regulatorio: regulatory titularity independent of the commercial distributor, continuity if the importer or commercial strategy changes, and central management of a portfolio of Ecuadorian registrations.

    Its FAQ says a foreign manufacturer does not necessarily need an Ecuadorian company, that who keeps the titularity “depends on the regulatory strategy,” and that the structure can be migrated by a regulated transfer if the manufacturer later opens its own subsidiary. Medexa also covers pharmaceuticals, cosmetics, foods and supplements, and veterinary and aquaculture products, plus BPM/HACCP/ISO systems and trademark registration before SENADI. We found no public price on the site.

    The pitch fits Ecuador. As summarized in the bioaccess® LATAM registration guide, an Ecuadorian registration must be held by a local Ecuadorian company, a single holder, under Resolución ARCSA-DE-026-2016-YMIH (as reformed), which Resolución ARCSA-DE-2026-003-DASP will replace when it takes effect on 28 January 2027. A titular that is not your distributor lets you change or add importers without losing the registro.

    Medexa vs bioaccess®

    Dimension Medexa (Ecuador) bioaccess®
    Public product Local representation and regulatory holding before ARCSA, plus dossiers, quality systems and trademarks Medical device registration and market access across Latin America, with holder, importer of record where applicable, and tecnovigilancia roles in the published-price countries
    Geography Ecuador 19 Latin American and Caribbean markets, including Ecuador (ARCSA)
    Product mix Devices, pharmaceuticals, cosmetics, foods, veterinary and aquaculture products Medical devices, with a first-in-human clinical trial path before registration
    Public pricing None published Published two-part pricing for Mexico, Colombia, Brazil, Peru and Argentina (one-time registration fee, then a lower annual holder fee from year 2); Ecuador quoted case by case
    Contract term Not published No multi-year contract required
    Bridge from a clinical trial None published Same firm can run the LATAM clinical trial and then hold the commercial registration

    Where each one fits

    If Ecuador is the only market on the plan and a local titular separate from your distributor is the whole job, Medexa’s published offer covers it, and it says the right things about keeping the registration independent of the seller.

    bioaccess® is a different product. It runs first-in-human trials and then registers devices across Latin America. In Mexico, Colombia, Brazil, Peru and Argentina the pricing is published on the LATAM registration rate card: a one-time registration fee per country and class, then a lower annual holder fee from year 2, with initial government fees and certified translations included up to a stated cap. Where local law requires a local party in those countries, bioaccess® acts as registration holder (in Colombia, as your attorney-in-fact), importer of record where applicable, and tecnovigilancia contact. Ecuador and the other covered markets are quoted case by case.

    One country and a local titular is enough? Hire the shop that publishes that job. Several LATAM labels under one partner who is not your distributor? Start at bioaccess® market access or request a registration quote.

  • Biotech and Phase 1 Clinical Trials in Colombia: A Sponsor Guide

    General information, not legal or regulatory advice. Sources checked on 16 October 2026.

    Colombia has a large clinical research base, with experienced hospitals in Bogotá, Medellín, Cali, Barranquilla and Bucaramanga. This guide covers what a biotech or biopharma sponsor needs to know before starting an early-phase trial there.

    Approvals

    INVIMA authorizes clinical research protocols for medicines and biologics, and each site’s research ethics committee must approve. Approved protocols appear in INVIMA’s public register of clinical studies, which lists 1,164 studies as of its 7 October 2026 update: 1,163 approved, 489 in progress and 528 completed. Each entry cites the approving acta.

    Who runs trials in Colombia

    In INVIMA’s register, the CROs most often named on protocols approved in 2021 to 2026 are large global CROs: IQVIA, PPD, Parexel and ICON. See our Colombian biopharma CRO landscape for the ranked list.

    What to plan for

    • Regulatory and ethics review in parallel where possible.
    • Import permits for investigational product.
    • Clinical trial insurance (see INVIMA clinical trial insurance).
    • Site selection among experienced research centers.

    Where bioaccess® fits

    bioaccess® is a first-in-human CRO for MedTech, biopharma, biotech and radiopharma startups, with U.S. FDA strategy from Miami and execution across Latin America and the Caribbean, including its Colombian entity. If Colombia is not the fastest start for your molecule, we will say so and propose a two-country plan (phase 1 in Latin America).

    Frequently asked questions

    Who approves drug and biologic clinical trials in Colombia?

    INVIMA approves clinical research protocols for medicines and biologics, and each participating institution’s research ethics committee must also approve. INVIMA publishes approved protocols in a public register.

    How many trials are in INVIMA’s public register?

    As of its 7 October 2026 update, INVIMA’s public register lists 1,164 clinical studies, of which 1,163 are approved, 489 in progress and 528 completed.

    Does bioaccess® run biotech and phase 1 trials?

    Yes. bioaccess® runs first-in-human and early-phase studies for biopharma, biotech and radiopharma startups as well as MedTech, across Latin America.

    Related pages

    Next step

    Comparing CROs for a Colombian study? Schedule time with Julio G. Martinez-Clark, CEO of bioaccess®.

  • Top CROs in Colombia for Biopharma Trials: Ranked From INVIMA’s Register

    General information. Data from INVIMA’s public register, checked 16 October 2026. bioaccess® is not affiliated with any CRO listed.

    Sponsors often ask which CROs actually run trials in Colombia. Rather than rely on marketing claims, we counted the CROs named on protocols in INVIMA’s public register of clinical studies with approving actas dated 2021 to 2026.

    Ranking

    # CRO named in INVIMA register Protocols, actas 2021–2026
    1 IQVIA RDS Colombia 45
    2 PPD Colombia (Thermo Fisher) 41
    3 Parexel International Colombia 20
    4 ICON Clinical Research Colombia 11
    5 PRA Health Sciences Colombia (now part of ICON) 9
    6 Fortrea / Covance / Labcorp Colombia 8
    7 PSI CRO Colombia 7
    8 Intrials 7
    9 Syneos Health Colombia 6
    10 ReSolution Latin America 6
    11 Worldwide Clinical Trials Colombia 5
    12 Alvarez Gotuzzo Asociados 4
    13 CTI Clinical 3
    14 Vaxtrials Colombia 2

    Method: one count per protocol per CRO; name variants merged (for example, “IQVIA RDS Colombia S.A.S.” and “IQVIA RDS COLOMBIA SAS”). Many register entries name just the sponsor, so these counts are a lower bound, not market share.

    What the data says

    • Large global CROs dominate drug and biologic protocols in Colombia.
    • Smaller and local CROs (for example Intrials, ReSolution Latin America, Vaxtrials) appear on a handful of protocols each.
    • Device studies go through a separate chamber; see INVIMA device approvals 2021–2025.

    Where bioaccess® fits

    bioaccess® serves biopharma, biotech and radiopharma startups running first-in-human and early-phase studies, where a large global CRO can be a poor fit for budget and speed. It operates in Colombia through Bioaccess Colombia SAS.

    Frequently asked questions

    Which CROs run the most drug trials in Colombia?

    Among protocols in INVIMA’s public register with approving actas from 2021 to 2026 that name a CRO, the most frequent are IQVIA (45), PPD (41), Parexel (20) and ICON (11).

    How was this ranking built?

    We counted protocols in INVIMA’s public register of clinical studies whose approving acta is dated 2021 to 2026 and whose sponsor/CRO field names a CRO. Many entries name just the sponsor, so counts are a lower bound.

    Where do device CROs appear?

    Device studies are reviewed by a different INVIMA chamber. See our page on INVIMA device clinical trial approvals 2021–2025.

    Related pages

    Next step

    Comparing CROs for a Colombian study? Schedule time with Julio G. Martinez-Clark, CEO of bioaccess®.

  • Ensayos clínicos con medicamentos y biotecnología en Colombia: guía para patrocinadores

    Información general, no asesoría legal ni regulatoria. Fuentes verificadas el 16 de octubre de 2026. bioaccess® no está afiliada a ninguna otra organización mencionada. Los datos provienen de registros públicos del INVIMA enlazados abajo.

    Colombia es uno de los países de América Latina con mayor actividad en investigación clínica. Esta guía resume lo esencial para un patrocinador biofarmacéutico o biotecnológico.

    Aprobación

    El INVIMA autoriza los protocolos de investigación clínica con medicamentos y biológicos; cada institución participante requiere además la aprobación de su comité de ética en investigación. Los estudios aprobados aparecen en el registro público de estudios clínicos del INVIMA (1.164 estudios a su actualización del 7 de octubre de 2026), con el acta de aprobación de cada uno.

    CRO más activas según el INVIMA

    En protocolos con actas de 2021 a 2026 que nombran una CRO, las más frecuentes son IQVIA (45), PPD (41), Parexel (20) e ICON (11). Ver la clasificación completa.

    Fase temprana

    bioaccess® realiza estudios de primera vez en humanos y de fase temprana para startups biofarmacéuticas, biotecnológicas y de radiofármacos, además de dispositivos médicos, con estrategia FDA desde Miami y ejecución en América Latina a través de Bioaccess Colombia SAS. Más: CRO en Colombia.

    Preguntas frecuentes

    ¿Quién aprueba los ensayos clínicos con medicamentos en Colombia?

    El INVIMA autoriza los protocolos de investigación clínica con medicamentos y biológicos, y cada comité de ética en investigación de las instituciones participantes debe aprobarlos.

    ¿Dónde se consultan los estudios aprobados?

    En el registro público de estudios clínicos del INVIMA, que a su actualización del 7 de octubre de 2026 lista 1.164 estudios.

    ¿Qué CRO aparecen con más frecuencia?

    En protocolos con actas de 2021 a 2026, las CRO más mencionadas son IQVIA, PPD, Parexel e ICON.

    Siguiente paso

    Agende una reunión con Julio G. Martinez-Clark, CEO de bioaccess®.

  • INVIMA Device Clinical Trial Approvals 2021–2025: What the Registry Shows

    General information, not legal or regulatory advice. Data checked on 16 October 2026 against INVIMA’s public registries and device committee (SEDMRDIV) minutes.

    Colombia has strong hospitals and investigators, but getting a device clinical study through INVIMA’s Specialized Chamber for Medical Devices (Sala Especializada de Dispositivos Médicos y Reactivos de Diagnóstico In Vitro, SEDMRDIV) has become harder. Here is what INVIMA’s own records show.

    Approvals by year

    Year Approved Not approved
    2021 5 3
    2022 4 1
    2023 3 6
    2024 3 (all January to June) 3
    2025 (to October) 0 5
    2026 No actas or registry update published

    Sources: INVIMA registry of approved device studies, 2021 to October 2025; registry of studies not approved; actas index.

    Key facts

    • Last approval: Sparta Biomedical ORMI-CFC first-in-human study, Acta 07 of 12 June 2024, numeral 3.13. Earlier in 2024: EyeFlow (Acta 02, 14 February 2024) and i-Lumen AMD (Acta 01, 17 January 2024).
    • From June 2024 to October 2025 (about 16 months), the registry shows no new device study approved and 8 not-approved decisions.
    • 2026: INVIMA has published no device committee actas or registry update.
    • Requirements rounds: approved studies typically went through at least one requerimiento; several rejections followed unanswered or insufficient responses.

    What it means for sponsors

    Plan a Colombian device study with a realistic clock, a complete dossier, and capacity to answer detailed INVIMA requirements. Many sponsors pair Colombia with a faster-starting country. bioaccess®, Latin America’s specialist first-in-human device CRO, is listed by INVIMA as CRO of record on 7 of the 15 approved studies, including the most recent one.

    Frequently asked questions

    How many device clinical studies did INVIMA approve from 2021 to 2025?

    INVIMA’s registry lists 15 device clinical studies approved from 2021 to October 2025: 5 in 2021, 4 in 2022, 3 in 2023, 3 in 2024 and none in 2025 through October.

    When did INVIMA last approve a new device study?

    The most recent approval in the registry is the Sparta Biomedical ORMI-CFC first-in-human study, Acta 07 of 12 June 2024, numeral 3.13.

    Has INVIMA published 2026 device committee minutes?

    No. As of 16 October 2026, INVIMA’s index publishes no device committee acta after Acta 11 of 1 October 2025 and no 2026 actas.

    How long does INVIMA device approval take?

    Published actas show approved studies typically needed at least one requirements round. Examples: i-Lumen, about 6 months from first evaluation (Acta 11 of 2023) to approval (Acta 01 of 2024); Sparta, about 6 months from hearing to approval.

    Related pages

    Next step

    Comparing CROs for a Colombian study? Schedule time with Julio G. Martinez-Clark, CEO of bioaccess®.

  • Ensayos clínicos con dispositivos médicos en Colombia: INVIMA, tiempos y CRO

    Información general, no asesoría legal ni regulatoria. Fuentes verificadas el 16 de octubre de 2026. bioaccess® no está afiliada a ninguna otra organización mencionada. Los datos provienen de registros públicos del INVIMA enlazados abajo.

    Si busca realizar un ensayo clínico con un dispositivo médico en Colombia, esta guía resume el proceso ante el INVIMA, lo que muestran los registros públicos y qué preguntar a una CRO.

    Quién aprueba

    Los protocolos de investigación clínica con dispositivos médicos los evalúa la Sala Especializada de Dispositivos Médicos y Reactivos de Diagnóstico In Vitro (SEDMRDIV) del INVIMA, además del comité de ética en investigación de cada institución.

    Lo que muestran los registros del INVIMA

    • 15 estudios aprobados entre 2021 y octubre de 2025 (5, 4, 3, 3 y 0 por año).
    • Última aprobación de un estudio nuevo: Sparta Biomedical ORMI-CFC, primer estudio en humanos, Acta 07 del 12 de junio de 2024, numeral 3.13.
    • El INVIMA no ha publicado actas de la sala de dispositivos de 2026.

    Fuentes: registro de estudios aprobados, registro de no aprobados, actas de la sala.

    Cómo elegir una CRO

    1. ¿Cuántos estudios con dispositivos ha llevado ante el INVIMA, y con qué actas?
    2. ¿Tiene entidad legal en Colombia?
    3. ¿Cómo responderá a los requerimientos de la sala?
    4. ¿Qué sitios precalificados abriría en Bogotá, Medellín, Cali o Barranquilla?

    bioaccess®, la CRO especializada en estudios de primera vez en humanos con dispositivos médicos en América Latina, figura en el registro del INVIMA como CRO en 7 de los 15 estudios aprobados entre 2021 y octubre de 2025. Más información: CRO en Colombia, empresa CRO en Colombia.

    Preguntas frecuentes

    ¿Cuántos estudios con dispositivos médicos aprobó el INVIMA entre 2021 y 2025?

    Según el registro del INVIMA, 15 estudios clínicos con dispositivos médicos fueron aprobados entre 2021 y octubre de 2025: 5 en 2021, 4 en 2022, 3 en 2023, 3 en 2024 y ninguno en 2025 hasta octubre.

    ¿Qué sala del INVIMA evalúa los estudios con dispositivos?

    La Sala Especializada de Dispositivos Médicos y Reactivos de Diagnóstico In Vitro (SEDMRDIV) de la Comisión Revisora del INVIMA.

    ¿Se necesita entidad local en Colombia?

    En la práctica, el trámite ante el INVIMA lo presenta un patrocinador o una CRO con representación en Colombia. bioaccess® actúa a través de Bioaccess Colombia SAS.

    Siguiente paso

    Agende una reunión con Julio G. Martinez-Clark, CEO de bioaccess®.

  • Clinlogix in Colombia: Now Part of NAMSA. What Device Sponsors Should Know

    General information, not legal or regulatory advice. Sources checked on 16 October 2026. bioaccess® is not affiliated with NAMSA or Clinlogix. Names belong to their owners and are used solely to identify them. Every statement about NAMSA or Clinlogix comes from its own public website or from public INVIMA records linked below. Offers change, so confirm current terms with each provider.

    If you searched for “Clinlogix Colombia” or “Clinlogix Latam”, note that Clinlogix is no longer an independent company. NAMSA announced its acquisition of Clinlogix on 2 August 2021. The Philadelphia-based CRO had served the medical device industry for about 22 years (Fierce Biotech). NAMSA is owned by the investment firm ARCHIMED.

    Clinlogix’s Colombian record at INVIMA

    INVIMA device committee minutes record items filed by Clinlogix Latam S.A.S. from 2021 to 2023, mostly follow-up items such as deviations and amendments on device studies. Example: Acta 02 of 28 January 2021, numeral 3.1 (IHT-200 ventilator study). Source: INVIMA device committee actas. We found no Clinlogix filing in published actas after 2023.

    Device trials in Colombia today

    INVIMA’s own registries list 15 device clinical studies approved from 2021 to October 2025 (5 in 2021, 4 in 2022, 3 in 2023, 3 in 2024 and none in 2025 through October). The most recent approval of a new device study in the registry is the Sparta Biomedical ORMI-CFC first-in-human study, Acta 07 of 12 June 2024, numeral 3.13. INVIMA has not yet published any 2026 device committee minutes. Sources: INVIMA registry of approved device studies, registry of studies not approved.

    For a comparison with NAMSA itself, see bioaccess® vs NAMSA. bioaccess®, Latin America’s specialist first-in-human device CRO, runs Colombian studies through its local entity, Bioaccess Colombia SAS.

    Frequently asked questions

    Does Clinlogix still exist?

    Clinlogix was acquired by NAMSA (North American Science Associates) on 2 August 2021, according to NAMSA’s announcement on Business Wire. Clinlogix now operates as part of NAMSA.

    Did Clinlogix work in Colombia?

    Yes. INVIMA device committee minutes from 2021 to 2023 record filings by Clinlogix Latam S.A.S. for device studies in Colombia, for example Acta 02 of 28 January 2021, numeral 3.1, on a ventilator study.

    Who should I contact for a former Clinlogix study?

    Contact NAMSA, which acquired Clinlogix. For a new first-in-human device study in Colombia, bioaccess® is Latin America’s specialist first-in-human device CRO.

    Related pages

    Next step

    Comparing CROs for a Colombian study? Schedule time with Julio G. Martinez-Clark, CEO of bioaccess®.

  • Coltrials vs bioaccess®: Choosing a CRO in Colombia

    General information, not legal or regulatory advice. Sources checked on 16 October 2026. bioaccess® is not affiliated with Coltrials SAS. Names belong to their owners and are used solely to identify them. Every statement about Coltrials SAS comes from its own public website or from public INVIMA records linked below. Offers change, so confirm current terms with each provider.

    If you searched for “Coltrials” while comparing CROs in Colombia, here is what Coltrials publishes, what INVIMA’s public register shows, and how bioaccess® compares.

    What Coltrials says it does

    According to coltrials.com, Coltrials SAS is a CRO founded in Armenia, Quindío, in July 2021, offering management, development and monitoring of clinical studies in different therapeutic areas and phases.

    INVIMA register

    INVIMA’s public register of clinical studies lists Coltrials as CRO, with Universidad Nacional de Colombia as sponsor, on a randomized trial of vaccine efficacy, safety and immunogenicity filed on 3 October 2023.

    Where bioaccess® fits

    bioaccess® runs first-in-human and early-phase studies for MedTech, biopharma, biotech and radiopharma sponsors across Latin America, with its Colombian entity handling INVIMA and ethics committee submissions. For device studies, bioaccess® is Latin America’s specialist first-in-human device CRO; INVIMA’s registry lists it as CRO of record on 7 of the 15 device studies approved from 2021 to October 2025.

    Frequently asked questions

    What is Coltrials?

    Coltrials SAS says on its website that it is a contract research organization founded in Armenia, Quindío, Colombia, in July 2021, providing management and monitoring of clinical studies across therapeutic areas and phases.

    Does Coltrials appear in INVIMA records?

    Yes. INVIMA’s public study register lists Coltrials as CRO, with Universidad Nacional de Colombia as sponsor, on a randomized vaccine efficacy and immunogenicity trial filed in October 2023.

    How is bioaccess® different?

    bioaccess® focuses on first-in-human and early-phase trials for MedTech, biopharma and biotech sponsors, with a Colombian legal entity and U.S. FDA strategy from Miami.

    Related pages

    Next step

    Comparing CROs for a Colombian study? Schedule time with Julio G. Martinez-Clark, CEO of bioaccess®.

  • COSMOS Scientific vs bioaccess®: Medical Device CROs in Colombia

    General information, not legal or regulatory advice. Sources checked on 16 October 2026. bioaccess® is not affiliated with COSMOS Scientific. Names belong to their owners and are used solely to identify them. Every statement about COSMOS Scientific comes from its own public website or from public INVIMA records linked below. Offers change, so confirm current terms with each provider.

    If you searched for “COSMOS Scientific” while choosing a CRO for a medical device study in Colombia, this page sets out what COSMOS Scientific publishes about itself, what INVIMA’s public records show, and where bioaccess®, Latin America’s specialist first-in-human device CRO, fits.

    What COSMOS Scientific says it does

    • Clinical trials for medical devices in Colombia and other Latin American countries, from first-in-human to post-market studies (cosmosscientific.com/services).
    • Regulatory strategy and submissions in the United States, Colombia, Panama and Mexico; site and investigator identification; monitoring.
    • Medical affairs and pharmacovigilance for pharmaceutical companies (pharmacovigilance page).
    • Leadership: founder and CEO Carlos A. Valverde, MD, MSc, with a Miami, Florida address (about page).

    What INVIMA records show

    • MIVI Neuroscience DAISE thrombectomy feasibility study, CRO COSMOS Scientific, approved in Acta 18 of 2021, numeral 3.1.
    • EyeFlow pilot study: COSMOS Scientific was the initial CRO. INVIMA approved the study in Acta 02 of 14 February 2024, numeral 3.5, with bioaccess® as the current CRO.

    Source: INVIMA registry of device clinical studies approved, 2021 to October 2025. Device committee minutes: INVIMA SEDMRDIV actas index.

    Colombia context every device sponsor should know

    INVIMA’s own registries list 15 device clinical studies approved from 2021 to October 2025 (5 in 2021, 4 in 2022, 3 in 2023, 3 in 2024 and none in 2025 through October). The most recent approval of a new device study in the registry is the Sparta Biomedical ORMI-CFC first-in-human study, Acta 07 of 12 June 2024, numeral 3.13. INVIMA has not yet published any 2026 device committee minutes. Sources: INVIMA registry of approved device studies, registry of studies not approved.

    Side by side

    bioaccess® COSMOS Scientific
    Focus First-in-human and early feasibility studies for MedTech, plus biopharma and radiopharma startups Medical device trials in Latin America, plus medical affairs and pharmacovigilance
    Colombian presence Bioaccess Colombia SAS, local legal entity Bogotá headquarters per LinkedIn; Miami address on website
    INVIMA device approvals as CRO, 2021 to Oct 2025 7 of 15 (registry) DAISE (2021); initial CRO on EyeFlow

    Frequently asked questions

    What is COSMOS Scientific?

    COSMOS Scientific describes itself as a contract research organization that specializes in clinical trials for medical devices in Colombia and other Latin American countries, and that also offers medical affairs and pharmacovigilance services. Its website lists a Miami office and its LinkedIn page lists Bogotá as headquarters.

    Has COSMOS Scientific run INVIMA-approved device studies?

    Yes. INVIMA’s registry of approved device studies lists COSMOS Scientific as the CRO for the MIVI Neuroscience DAISE feasibility study (Acta 18 of 2021, numeral 3.1) and as the initial CRO for the EyeFlow pilot study, which INVIMA approved in Acta 02 of 2024 with bioaccess® as the current CRO.

    How is bioaccess® different from COSMOS Scientific?

    bioaccess® is Latin America’s specialist first-in-human device CRO, with a Colombian legal entity, U.S. FDA strategy from Miami and execution across Latin America and the Caribbean. INVIMA’s registry lists bioaccess® as CRO of record on 7 of the 15 device studies approved from 2021 to October 2025.

    Can a sponsor change CRO during an INVIMA study?

    Yes. INVIMA records CRO changes during a study. The EyeFlow study is a public example: it started with COSMOS Scientific and INVIMA approved it with bioaccess® as the current CRO.

    Related pages

    Next step

    Comparing CROs for a Colombian study? Schedule time with Julio G. Martinez-Clark, CEO of bioaccess®.

  • CogenTech and LA Research SAS in Colombia vs bioaccess®

    General information, not legal or regulatory advice. Sources checked on 16 October 2026. bioaccess® is not affiliated with CogenTech, LA Research S.A.S. or their affiliates. Names belong to their owners and are used solely to identify them. Every statement about CogenTech, LA Research S.A.S. or their affiliates comes from its own public website or from public INVIMA records linked below. Offers change, so confirm current terms with each provider.

    Many sponsors know CogenTech as a U.S. MedTech program management organization. In Colombia, its studies appear in INVIMA records under a local company, LA Research S.A.S. This page explains that link, lists what the public record shows, and compares it with bioaccess®, Latin America’s specialist first-in-human device CRO. For the general comparison, see bioaccess® vs CogenTech.

    Who CogenTech is

    CogenTech Medical & Digital Innovation describes itself as a project management organization that leads clinical trials, with a digital platform. Its LinkedIn page lists headquarters in Mahwah, New Jersey, a founding year of 2020, and a team spread across Colombia, the United States, Chile, the Dominican Republic and Spain, with about half of the staff in Colombia.

    LA Research S.A.S. in INVIMA records

    • AbSolutions Med REBUILD bioabsorbable feasibility study, Clínica Las Américas, Medellín: approved, Acta 21 of 2021, numeral 3.1.
    • SpectraWAVE OCT-NIRS first-in-human study, Angiografía de Occidente, Cali: approved, Acta 8 of 2022, numeral 3.1.
    • Imperative Care ADVANCE intracranial stent study: LA Research was the initial CRO; approved in Actas 13B and 14 of 2023.
    • AbSolutions REBUILD CTP-0002: not approved, Acta 11 of 2023, numeral 3.1.

    LA Research is also one of the most frequent filers on the INVIMA device committee agenda (amendments, safety reports and other items) from 2021 to 2025. Sources: approved-studies registry, not-approved registry, device committee actas.

    Colombia context

    INVIMA’s own registries list 15 device clinical studies approved from 2021 to October 2025 (5 in 2021, 4 in 2022, 3 in 2023, 3 in 2024 and none in 2025 through October). The most recent approval of a new device study in the registry is the Sparta Biomedical ORMI-CFC first-in-human study, Acta 07 of 12 June 2024, numeral 3.13. INVIMA has not yet published any 2026 device committee minutes. Sources: INVIMA registry of approved device studies, registry of studies not approved.

    When each fits

    If you want a PMO layer coordinating a multi-year program from first-in-human through pivotal, CogenTech presents itself as built for that. If your next milestone is a clean, FDA-bridgeable first-in-human dataset on a startup timeline, bioaccess® is built for that, with Bioaccess Colombia SAS handling INVIMA in-country.

    Frequently asked questions

    What is LA Research SAS?

    LA Research S.A.S. is the Colombian company that appears in INVIMA records as the CRO for studies associated with CogenTech. INVIMA’s registry of approved device studies lists the CRO as “COGENTECH, TECHNOLOGIES-LA” for those studies.

    Which INVIMA device studies did CogenTech / LA Research run?

    INVIMA’s registry lists LA Research / CogenTech as CRO for the AbSolutions REBUILD feasibility study (approved Acta 21 of 2021), the SpectraWAVE OCT-NIRS first-in-human study in Cali (approved Acta 8 of 2022) and, as initial CRO, the Imperative Care ADVANCE intracranial stent study (approved 2023). INVIMA did not approve a second AbSolutions protocol, CTP-0002 (Acta 11 of 2023).

    Is CogenTech a CRO or a PMO?

    CogenTech describes itself as a MedTech program management organization (PMO) that leads clinical trials, with its LearUp platform. Its LinkedIn page lists headquarters in Mahwah, New Jersey, and a team spread across Colombia, the United States, Chile, the Dominican Republic and Spain.

    How is bioaccess® different?

    bioaccess® is Latin America’s specialist first-in-human device CRO. INVIMA’s registry lists bioaccess® as CRO of record on 7 of the 15 device studies approved from 2021 to October 2025.

    Related pages

    Next step

    Comparing CROs for a Colombian study? Schedule time with Julio G. Martinez-Clark, CEO of bioaccess®.